bladder%20cancer
BLADDER CANCER

Bladder cancer is a heterogenous neoplasm that ranges from non-life-threatening, low-grade, superficial papillary lesions to high-grade invasive tumors that often metastasizes at the presentation.

It is the most common cancer involving the urinary system and it is the 11th most commonly diagnosed in the world.

Microscopic or gross painless hematuria is the most common presenting complaint.

Surgical Intervention

Transurethral Resection of Bladder Tumors (TURBT)

  • Standard treatment for non-muscle-invasive bladder tumors (Ta, T1, Tis) & cTa low-grade tumors w/ the goal of removing all visible lesions
  • Therapeutic option in patients w/ muscle-invasive bladder tumor if tumor growth is limited to the superficial muscle layer & if re-staging biopsies are negative for invasive tumor
  • The strategy of resection depends on the size of the lesion
    • In small tumors (<1 cm in diameter), en bloc resection can be done, where the specimen contains the complete tumor plus part of the underlying bladder wall including muscle
    • For large tumors, resection is done in parts, which include exophytic part of the tumor, the underlying bladder wall w/ the detrusor muscle & the edges of the resection area
    • Separate resection of larger tumors provides good information about the vertical & horizontal extent of the tumor & helps to improve resection completeness
  • Complete & correct TURBT is essential to achieve a good prognosis
    • An absence of detrusor muscle in the specimen is associated w/ a significantly higher risk of residual disease, early recurrence & tumor understaging
  • Selected mapping biopsies & transurethral biopsy of the prostate must be considered if sessile lesion or Tis or high-grade disease is suspected
  • A second TURBT is performed:
    • After 2-3 weeks of incomplete initial TURBT
    • If there is no muscle in the specimen after initial resection, w/ the exception of TaG1
    • When a high-grade, primary CIS, T1 tumor & possibly a Ta has been detected at the initial TURBT
  • A second TURBT can increase recurrence-free survival, improve outcomes after Bacillus Calmette-Guerin (BCG) treatment & provide prognostic information

Radical Cystectomy

  • Indicated in patients w/ non-muscle-invasive bladder cancer that have failed BCG treatment & in patients w/ highest risk of tumor progression
  • Standard curative treatment for patients w/ muscle-invasive bladder cancer
    • Appropriate procedure in men involves cystoprostatectomy
    • While in women a cystectomy & a hysterectomy
    • Followed by the formation of a urinary diversion
  • Should include the essential pelvic lymph node dissection
  • Immediate radical cystectomy is suggested in patients w/ non-muscle invasive bladder cancer if:
    • TURBT staging accuracy for T1 tumors is low
    • Patients w/ non-muscle invasive bladder cancer experience disease progression to muscle-invasive disease
  • Delaying cystectomy for >3 months may increase the risk of progression & cancer-specific mortality

Partial Cystectomy

  • Indicated if the lesions develop on the dome of the bladder & have no associated Tis in other areas of urothelium
  • The procedure begins w/ a laparotomy (intraperitoneal) & resection of the pelvic lymph nodes
    • If the intraoperative findings preclude a partial cystectomy, a radical cystectomy is performed

Fulguration

  • Fulguration without biopsy is considered in patients w/ recurrent non-muscle-invasive bladder cancer if all of the following are present:
    • No previous bladder cancer that was intermediate- or high-risk
    • A disease-free interval of at least 6 months
    • Solitary papillary recurrence
    • A tumor diameter of ≤3 mm
  • In patients w/ a history of small, Ta LG/G1 tumors, fulguration of small papillary recurrences on an outpatient basis can reduce the therapeutic burden & can be a treatment option
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.